Jacobs Levy Equity Management Inc. Sells 220,307 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Jacobs Levy Equity Management Inc. lowered its stake in Kodiak Sciences Inc. (NASDAQ:KOD) by 37.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 360,476 shares of the company’s stock after selling 220,307 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in Kodiak Sciences were worth $3,587,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in KOD. Price T Rowe Associates Inc. MD raised its stake in shares of Kodiak Sciences by 10,982.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,268,509 shares of the company’s stock worth $12,622,000 after buying an additional 1,257,063 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of Kodiak Sciences in the fourth quarter worth about $11,338,000. Boxer Capital Management LLC bought a new position in shares of Kodiak Sciences in the fourth quarter worth about $9,950,000. Silverarc Capital Management LLC raised its stake in shares of Kodiak Sciences by 100.0% in the fourth quarter. Silverarc Capital Management LLC now owns 1,000,000 shares of the company’s stock worth $9,950,000 after buying an additional 500,000 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Kodiak Sciences by 545.7% in the fourth quarter. Invesco Ltd. now owns 519,010 shares of the company’s stock worth $5,164,000 after buying an additional 438,635 shares during the period. Institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating and set a $3.00 target price on shares of Kodiak Sciences in a research note on Monday, March 31st.

Kodiak Sciences Trading Down 2.2%

Shares of KOD opened at $3.94 on Thursday. The business’s 50 day moving average is $3.29 and its 200 day moving average is $5.49. The company has a market capitalization of $207.84 million, a PE ratio of -1.08 and a beta of 2.42. Kodiak Sciences Inc. has a 12-month low of $1.92 and a 12-month high of $11.60.

Kodiak Sciences (NASDAQ:KOD) last issued its earnings results on Wednesday, May 21st. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.20). Equities research analysts predict that Kodiak Sciences Inc. will post -3.45 earnings per share for the current year.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.